Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02192983
Other study ID # zswy002
Secondary ID
Status Completed
Phase N/A
First received July 15, 2014
Last updated November 30, 2015
Start date November 2008
Est. completion date May 2015

Study information

Verified date November 2015
Source Shanghai Zhongshan Hospital
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Observational [Patient Registry]

Clinical Trial Summary

This study is designed to assess what is the better neoadjuvant chemotherapy regimen for patients with initially unresectable locally advanced gastric cancer.


Recruitment information / eligibility

Status Completed
Enrollment 242
Est. completion date May 2015
Est. primary completion date May 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- more than 2 regional bulky lymph nodes macroscopic tumor type is either the Borrmann type 4 or large type 3 tumor invades adjacent structures (T4b)

Exclusion Criteria:

- peritoneal metastasis confirmed by CT scan lung metastasis, liver metastasis, pleural effusion, and/or other distant metastasis

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
China Shanghai Zhongshan Ethics Committee Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Tianshu Liu

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response rate 6 months after diagnosis No
See also
  Status Clinical Trial Phase
Recruiting NCT05545436 - Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer Phase 2
Not yet recruiting NCT05524974 - Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes Phase 2
Active, not recruiting NCT03192735 - Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT03961373 - Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer Phase 3
Not yet recruiting NCT05610332 - Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes Phase 3
Recruiting NCT02855788 - Metronomic Chemotherapy in Advanced Gastric Cancer Phase 2
Not yet recruiting NCT02365896 - Comparison of Short Term Outcomes Between Totally Laparoscopic and Laparoscopy-Assisted Distal Gastrectomy With Billroth-II Reconstruction and D2 Lymphadenectomy for Locally Advanced Gastric Cancer N/A
Not yet recruiting NCT06459921 - Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer Phase 2
Recruiting NCT05141747 - A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer. Phase 2
Active, not recruiting NCT06277453 - Effect of Adjuvant Chemotherapy Cycles on Patients With Node-negative Gastric Cancer Following Neoadjuvant Chemotherapy
Recruiting NCT05528367 - Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Phase 2
Recruiting NCT04792515 - Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer Phase 2
Active, not recruiting NCT06235164 - The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer
Recruiting NCT03322969 - Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy Phase 2
Recruiting NCT02302794 - A Multicenter Clinical Trial on Laparoscopic Gastric Cancer Surgery Compared With Open Surgery Phase 3